


# PlentiPlex™ MYD88

## CANCER DIAGNOSTIC

PlentiPlex™ MYD88 L265P assay utilises PentaBase's in-house production of custom DNA molecules based on our Intercalating Nucleic Acid (INA) chemistry.



PlentiPlex™ MYD88 L265P assay is created as an innovative product that enables further personalised cancer treatment for every patient, contributing to a healthier and safer society. PlentiPlex™ MYD88 L265P assay is intended to assist oncologists in precise treatment planning within an hour. The assay provides a fast and simple diagnosis of lymphoma, based on the examined mutation down to 0.25 percent of the human gDNA sample retrieved.

**Results in less than one hour**

**Reliable and simple readout**

**Minimal hands-on time**

**Enables personalised cancer treatments**

Version 1.0

# PRODUCT INFORMATION OF PlentiPlex™ MYD88

## Formats

Ready-To-Use  
Dispense Ready

## Result Time

≤ 60 minutes

## Shipment

≤ 20°C or on dry ice

## Loci

MYD88 L265P

## Reagents and Materials

DNA oligomers modified with fluorophores, quenchers and proprietary PentaBases

## Approved Instruments

BaseTyper™ 48  
Rotor-Gene (Qiagen)  
MX3000P/3005P (Agilent)  
LightCycler® 96 + 480 (Roche)  
CFX96™ (Bio-Rad)  
ABI 7500/7900HT (Applied Biosystems)  
MIC (Bio Molecular Systems)

## Configuration

Simplex and multiplex

## Design

Reference Assay  
Mutation Assay

## Storage

Range between -20°C and -80°C

## Content

Ready-To-Use: 12 or 60  
Dispense-Ready: 20 or 50

## Detection Sensitivity

0.25% of a human genomic DNA  
(gDNA) sample

## Equipment Required

Template DNA (extracted patient gDNA)  
Real-Time PCR instrument  
Other relevant products (for more information visit [www.pentabase.com](http://www.pentabase.com))